We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Pfizer’s COVID-19 Vaccine Shows Mild-To-Moderate Side Effects in Phase 3 Clinical Trial

By HospiMedica International staff writers
Posted on 17 Sep 2020
Print article
Image: Pfizer’s COVID-19 Vaccine Shows Mild-To-Moderate Side Effects in Phase 3 Clinical Trial (Photo courtesy of Pfizer)
Image: Pfizer’s COVID-19 Vaccine Shows Mild-To-Moderate Side Effects in Phase 3 Clinical Trial (Photo courtesy of Pfizer)
Pfizer Inc. (New York, NY, USA) has stated that participants in an ongoing late-stage study who were given either its experimental COVID-19 vaccine or a placebo were showing mild-to-moderate side effects.

Pfizer is developing the investigational vaccine candidate in partnership with Biopharmaceutical New Technologies (BioNTech Mainz, Germany). The experimental COVID-19 vaccine is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities.

Pfizer is conducting a placebo-controlled trial to evaluate the safety and efficacy of the COVID-19 vaccine in up to 44,000 participants who will receive either the vaccine or placebo. During an investor conference call, Pfizer executives confirmed that it had enrolled over 29,000 people for the trial and had given a second dose of the experimental COVID-19 vaccine to more than 12,000 study participants. The COVID-19 vaccine had demonstrated a "mostly mild to moderate” safety profile, with rare instances of severe or grade 4 side effects. According to the company, the study participants who had been given only the first dose of COVID-19 vaccine experienced mainly fatigue and headache, with others reported muscle pain, diarrhea, chills and joint pain.

Pfizer has assured that it continues to scrutinize the safety and tolerability of the vaccine in its study. The company also said that an independent data monitoring committee could recommend halting the study any time, although it had not done so until now.

Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
EEG System
BRAIN QUICK

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.